Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

risdiplam

- PMLiVE

Bayer’s Vitrakvi scores first EU tumour-agnostic drug approval

Will likely face competition soon from rival Rozlytrek

Roche - Basel

Roche wins FDA breakthrough for Gazyva in lupus nephritis

Drug originally approved as a lymphoma treatment

- PMLiVE

Roche preps filings for Herceptin/Perjeta combination

Potential defence against biosimilar competition

Roche Basel Switzerland

Roche presents new data in NMOSD, could challenge Alexion’s Soliris

Reduced risk of relapse by 55%

AstraZeneca AZ

Can AZ’s Imfinzi challenge Tecentriq in small cell lung cancer?

New data shows improvement in overall survival

Roche Basel Switzerland

Roche scores EU approval twice for Tecentriq in lung cancer

Carves out space in a market dominated by MSD's Keytruda

- PMLiVE

Genentech agrees trade secret theft settlement with Taiwan’s JHL

Three ex-Genetech workers pleaded not guilty to criminal theft charges

Roche Basel Switzerland

Roche’s flu drug Xofluza scores phase 3 primary endpoint

Demonstrates efficacy as a preventative treatment

- PMLiVE

Novartis scores promising phase 3 MS study

Takes fight to Roche’s blockbuster ocrevus

- PMLiVE

Tecentriq approved in Europe for triple negative breast cancer

Roche can dominate in niche setting

- PMLiVE

‘Therapeutic overcrowding’ could hit big pharma returns

Jefferies analysts identify most at-risk companies

- PMLiVE

Roche’s Hemlibra scores broader NHS funding

Expands to around 2,000 patients in England

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links